Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palisade Bio ( (PALI) ) has shared an update.
On September 4, 2025, Palisade Bio, Inc. introduced a Phantom Unit Plan, allowing the Compensation Committee to grant up to 10 million cash-settled phantom units to employees, directors, and consultants. This plan, exempt from NASDAQ shareholder vote requirements, ties the value of these units to the company’s common stock but does not confer ownership rights. The plan will last for ten years, with specific vesting and settlement schedules. Additionally, executive officers and directors received specific grants under this plan, with vesting schedules and potential accelerated vesting terms outlined. The company also amended executive employment agreements for key officers, detailing salary, bonus eligibility, and severance benefits in case of involuntary termination.
The most recent analyst rating on (PALI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Average Trading Volume: 2,214,891
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.77M
See more data about PALI stock on TipRanks’ Stock Analysis page.